Posted by Michael Wonder on 04 May 2022
Mirvie receives FDA breakthrough device designation for first test designed to indicate risk of preeclampsia months before symptoms occur
3 May 2022 - Breakthrough has the potential to address a leading cause of maternal mortality that impacts millions of pregnancies each year.
Mirvie today announced the company received U.S. FDA breakthrough device designation for its test to indicate a woman’s individualised risk of developing preeclampsia before symptoms occur.
